O rgan donation after cardiac death (DCD) is increasing markedly in the United Kingdom, United States, and some parts of Europe, and controlled DCD donors now represent around one third of all deceased donors in the United Kingdom (1) (2) (3) . The outcome after transplantation with organs from DCD donors is generally good, and such donors undoubtedly represent an important addition to the organ donor pool (4 -7) . However, recovery of organs from DCD donors is particularly demanding in terms of logistics and resources, particularly because not all potential DCD donors proceed to organ donation and for those who do, the timing of donation is both variable and unpredictable (8, 9) . Moreover, DCD donors provide fewer transplantable organs per donor than donors with brain death (donation after brain death [DBD] ) (10) . DCD donors are not currently used to provide hearts for transplantation, and there are concerns that in some cases, other organs from DCD donors may be at risk of additional complications (5, 6) .
Although there has been an increase in the number of DCD donors in the United Kingdom, the number of DBD donors has gradually decreased, and there is concern, based mainly on anecdotal evidence, that many donors who might previously have become DBD donors are proceeding instead to DCD. The suggestion that the availability of DCD may have an adverse impact on DBD is consistent with data from The Netherlands where the successful introduction of a large program of DCD has corresponded with a decrease in DBD (1) .
We have sought to clarify the likely extent to which the gradual decline in DBD within the United Kingdom over the past decade may be attributed to the increase in DCD. In addition to national data on deceased donor demographics, we have analyzed information arising from the UK audit of all deaths in intensive care units (ICUs) to identify potential deceased donors.
RESULTS

Deceased Donor Trends
The trends in deceased organ donation in the United Kingdom over the past decade, obtained from analysis of data from the UK Transplant Registry held by National Health Service Blood and Transplant, are shown in Figure 1 . Figure 1 (B), and it can be seen that for both DBD and DCD donors, stroke remains the major cause of death, accounting for 43.4% of DCD deaths and 67.4% of DBD deaths in 2008 to 2009. There was a decline in the proportion of deaths attributable to trauma in DBD donors during the 10-year period from more than 22% in 1999 to 2000 to 11% 2008 to 2009, whereas trauma deaths still accounted for more than 15% deaths in DCD donors in 2008 to 2009. The mean number of organs retrieved for transplantation from an individual donor provides a helpful indicator of organ availability and utilization over time according to donor type (DBD and DCD). The number of organs retrieved per donor increased gradually for both DBD and DCD donors during the 10-year study period (Fig. 1C) , although the mean number of organs donated per DCD donor remained less than that per DBD donor (mean 2.7 organs/donor vs. 4.0 organs/donor respectively in 2008 -2009). All deceased donors were further categorized according to the American classification for extended criteria kidney donors (11) . During the 10-year study period, the percentage of DBD donors categorized as extended criteria donors remained relatively stable at approximately 25%, whereas donation from extended criteria DCD donors increased markedly from less than 5% in 1999 to 2001 to 28% in 2008 to 2009, which marginally exceeded that for DBD donors (Fig. 1D) .
Audit of Potential Deceased Donors
The UK wide audit of potential deceased organ donors was initiated in April 2003 to determine the true potential for solid-organ donation and identify shortcomings of the deceased organ donation system (12) . It has undergone several revisions since its inception, but during the study period (April 1, 2004 to March 31, 2009), it aimed to audit comprehensively all deaths occurring in patients younger than 76 years in ICU (excluding those in cardiothoracic ICU) and determine whether potential donors were identified and appropriate steps were taken to enable them to proceed to organ donation. During the 5-year period (April 2004 to March 2009), a total of 78,338 deaths were included in the audit (Fig. 2) . The annual number of deaths reported remained relatively constant during the audit period (mean 15,668 deaths/year). A total of 8345 (10.7%) of patients who died in ICU were found to be potential candidates for brain stem death testing, on the basis that they were deeply comatose (Glasgow Coma Score 3), apparently apnoeic on a mechanical ventilator and had unreactive pupils. During the 5-year audit period, there was a gradual decline (of 22.5%) in the number of potentially brain-dead patients (Fig. 3A) .
The majority (6323 or 75.8%) of potentially brain-dead patients were formally tested for brain stem death, and of these, 6160 (97.4%) were found to fulfill the diagnostic criteria for brain death. It was notable that the percentage of potential brain-dead patients who were tested for brain stem death increased during the audit period from 72. (Fig. 3A) .
Of the 6160 patients who were confirmed brain stem dead, 39 patients (0.4%) had absolute medical contraindications to organ donation (HIV or known or suspected variant Creutzfeldt-Jakob disease). For the purposes of the audit, the remaining 6121 patients were defined as the potential pool of DBD organ donors. Approximately half (2980 or 48.5%) of these patients subsequently became organ donors with the remainder not progressing to organ donation, predominantly because of additional medical contraindications to donation or lack of consent to donation from the donor family.
The pathway for patients who died in ICU becoming DCD donors was more varied than that for DBD organ donors. During the 5-year audit period, the majority (85%) of the 667 eventual DCD donors reported through the Potential Donor Audit (PDA) were from the group of patients who did not fulfill the preconditions and exclusion criteria for the diagnosis of brain stem death and who therefore died after the withdrawal of cardiorespiratory support. However, 78 (12%) DCD donors were patients who could have been, but were not, tested for brain death, and 23 (3%) were tested but found not to fulfill the criteria for brain death (Fig. 2) . The proportion of DCD donors from these two groups of patients declined in the last 4 years of the audit from 20% in 2005 to 2006 to 13% in 2008 to 2009. There were 5582 potential DCD donors, after excluding those patients with any of the following: absolute medical contraindications (HIV or known or suspected variant Creutzfeldt-Jakob disease) to organ donation, "relative medical contraindications" to donation, patients over locally agreed age limits, patients from centers that did not have established DCD donor programs, and patients for whom supportive treatment was not withdrawn. Of the po- tential DCD donors, a total of 667 (11.9%) became organ donors during the 5-year audit period (Fig. 2) . Of the actual DCD donors, a total of 56 (8.4%) had previously been diagnosed with brain stem death but became DCD donors because of a lack of consent for DBD donation or because they developed hemodynamic instability. However, the conversion rate for those identified as potential DCD donors to those who became actual donors increased markedly during the audit period from 5 (Fig. 3B) .
DISCUSSION
DCD has become an increasingly important source of donor organs in several countries, including the United Kingdom, but concern has been expressed that DCD donor programs may contribute to a failure to realize the full potential for DBD donation (13) . This study is one of the first to attempt to examine this issue, and our findings suggest that that the large majority of DCD donors were not potential DBD donors but instead represent an additional source of deceased donor organs.
Analysis of the UK Transplant Registry confirms that the increase in DCD donor numbers has coincided with a modest decrease in the number of DBD donors, as also observed in The Netherlands (1), although the overall number of deceased donors (i.e., DBD and DCD donors) has increased. However, the results from the present audit of deaths in ICU suggest that the decline in DBD organ donors correlates closely with a decline in the number of patients who fulfill the criteria for brain stem death testing (apnoea, coma, and fixed dilated pupils). Moreover, the number of actual DBD organ donors, as a proportion of all potential DBD donors (i.e., those patients who fulfilled the criteria for brain stem death testing), increased progressively during the 5-year period of the UK wide audit of all potential donors, indicating that better use has been made of a diminishing potential donor pool. It is disappointing that around one fifth of those patients with possible brain stem death did not have brain stem death tests performed. The reasons for this were not recorded during the audit period but could include donor cardiovascular instability and lack of consent from relatives. More clarity on this will be forthcoming because the UK PDA has recently been modified to capture the reasons why those with possible brain stem death are not tested.
The reasons for the gradual decline in the number of DBD donors in the United Kingdom are not fully understood but the decrease corresponds with a marked reduction in trauma deaths over the same time period due, at least in part, to improved road safety (14) . There have also been major changes to neurosurgical practice, notably increasing use of decompressive craniectomy for malignant cerebral edema caused by trauma or ischemia and early interventional radiology for the management of ruptured intracranial aneurysms, both of which may prevent the development of brain stem death (15, 16) .
Although only a minority of DCD donors in the United Kingdom are likely to be brain stem dead at the time of treatment withdrawal, a more fundamental question, and one that is much more difficult to answer, is how many potential DCD donors would have eventually become brain stem dead had treatment withdrawal not taken place. This is not a question that can be easily addressed, although the very striking international variation in the number of DBD donors-variation that cannot be explained simply on the basis of family consent rates-suggests that the answer lies either in variations in the epidemiology of acute brain injury, the effectiveness of its treatment or the management strategies when the potential for recovery has been lost. For instance, in 2009, Spain reported a total of 32 DBD donors pmp compared with a total of only 10.5 pmp in the United Kingdom (2, 17) . These differences cannot be attributed to variations in family consent rates (85% vs. 62%, respectively) and point instead to a real difference in the incidence of diagnosed brain stem death. It is also worthy of note that although uncontrolled DCD donors make a modest contribution to the total deceased donor pool in Spain (2 donors pmp), there is no controlled DCD program, suggesting that treatment withdrawal on the grounds of futility-such a prominent feature of critical care practice in the United Kingdom-is relatively uncommon in Spain. This study is unable to provide a definitive answer to this most important question, because the audit of deaths in ICU is unable to quantify those patients who may have proceeded eventually to develop brain stem death had treatment not been withdrawn. The duration of ICU stay was not recorded in the PDA but may have been useful because changing trends of ICU stay for DCD and DBD potential donors might have indicated changes in donor management during the study period. Current practice in the United Kingdom (and in most international transplant communities) is based on the fundamental principle that decision making over the withholding or withdrawal of treatment should be determined by what is considered to be in a patient's overall benefit. Although guidance recently issued from the Department of Health in England describes the circumstances in which delaying treatment withdrawal to facilitate DCD can be considered to be lawful, there is currently no parallel legal framework that covers potential DBD donors (18, 19) . Indeed, any suggestion that treatments should be continued primarily to promote the potential for DBD are likely to be met with considerable professional caution and resistance (20) .
The increase in the number of DCD donors in the United Kingdom looks set to continue. The ongoing donor audit reported here probably underestimates substantially the true number of potential DCD donors because the criteria described on the audit form for excluding potential DCD donors from further consideration is, unlike the DBD audit form, only loosely defined. For example, the absence of a local DCD donor program and a broad range of medical contraindications were allowed as exclusion criteria on the audit form (although this has been improved in the new PDA data collection introduced from October 2009), which undoubtedly led to potential DCD donors being overlooked inappropriately. It was also notable that during the past decade, as the number of DCD donors increased, so too did the proportion of extended criteria DCD donors (identified on the basis of age, cause of death, and terminal serum creatinine), presumably indicating an increased willingness by transplant clinicians to accept DCD donor organs for transplantation on the basis that they expected transplant outcomes to be satisfactory.
In conclusion, the findings reported here do not support the suggestion that significant numbers of DCD donors are, or are likely to be, brain stem dead at the time of treatment withdrawal, although it is acknowledged that even the small numbers that have been identified would make an important contribution to heart transplant programs in the United Kingdom. DCD donation is currently a valuable source of organs for transplantation, and this study highlights the potential for further expansion of DCD donation in the United Kingdom. The transplant community should continue to work with colleagues in critical care to ensure that all patients are given the option of donation as a component of end of life care.
MATERIALS AND METHODS
Population
This study is based on two databases maintained by National Health Service Blood and Transplant. The first is the UK Transplant Registry to which all the UK solid-organ transplant centers provide mandatory demographic and follow-up data for actual organ donors and recipients. The second, as part of the PDA (12) , collects data on all deaths of patients younger than 76 years in all of the 341 noncardiothoracic ICUs in 284 different UK hospitals.
Deceased Donor Trends
Data from the UK Transplant Registry was analyzed between April 1, 1999 and March 31, 2009, to identify trends in donor characteristics. Extended criteria donors were defined as those donors who were older than 60 years or were aged between 50 and 60 years and had two of the following conditions: hypertension, terminal creatinine of more than 132 mmol/mL, or death resulting from stroke (11) .
The Potential Donor Audit
The PDA (12) collects data in a hierarchical fashion (Fig. 2) . Basic demographic information (nonpatient identifiable) is obtained for all patients younger than 76 years who die in a noncardiothoracic ICU, together with date, time, and cause of death. This is followed by questions concerning whether brain stem death was a likely diagnosis (i.e., the potential donor was apnoeic, unconscious and with fixed and dilated pupils) and whether brain stem tests were performed and, if so, their outcome. The potential DBD pool is defined as comprising those patients whose death is confirmed using neurologic criteria and who do not have an absolute medical contraindication to donation (at the time of the study these included suspected CreutzfeldtJakob disease or infection with HIV). The PDA was interrogated between April 2004 and March 2009 to identify any trends in the rate of brain stem testing and conversion rates (the proportion of potential donors becoming actual donors).
Statistics
Statistics was performed using SAS version 9.1 (SAS Institute Inc., NC).
